TOP - May 2018, Vol 11, No 1
At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Jaime Anderson, PharmD, BCOP, reviewed recent efficacy and safety data on immune checkpoint inhibitor regimens in melanoma, and discussed disease-specific characteristics that may guide treatment-planning decisions.
According to the results of 2 separate clinical trials presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide reduced the risk for metastasis and prolonged metastasis-free survival in patients with nonmetastatic castrate-resistant prostate cancer.
According to Dr Tsai, the length of optimal treatment can vary from patient to patient, but treatment discontinuation studies and longer follow-up periods are needed before definitive recommendations can be incorporated into survivorship care plans.
POUT was one of the most often tweeted clinical trials from the meeting, where it was met with much praise. “It is a triumph getting behind a trial with a low-incidence tumor. UTUC is a relatively rare disease, and it is safe to say it is more lethal than muscle-invasive bladder cancer.
Progression-free survival (PFS) was extended by 3.5 months with first-line atezolizumab (Tecentriq) plus bevacizumab (Avastin) in patients with metastatic renal-cell carcinoma (RCC) versus standard-of-care sunitinib (Sutent) in the phase 3 IMmotion151 clinical trial presented at the 2018 Genitourinary Cancers Symposium
Results 1 - 10 of 11